Compare Merck & Co., Inc. (MRK) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SOLAI Limited — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Merck & Co., Inc. is far larger — about 21946.1× SOLAI Limited's market cap, and Merck & Co., Inc. pays a 2.29% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| MRK | SLAI | |
|---|---|---|
Market Cap | $366.28B | $16.69M |
Sector | Health | Technology |
52-Week High | $156.43 | $21.63 |
52-Week Low | $77.60 | $2.74 |
Enterprise Value | $413.04B | $16.33M |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SLAI trades at $3.72 with no recent price movement, showing technical bullish signals despite fundamental challenges. The company reported negative financial metrics including -$33.88M net income and -134.63% net margin for 2025, though it beat Q2 2025 EPS expectations. Recent corporate actions include a 7:1 reverse stock split effective July 2026 and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial operational risks offset by low valuation multiples. Investment opportunity exists only for risk-tolerant investors betting on the AI infrastructure turnaround, while delisting proceedings and persistent losses present severe downside risks requiring careful monitoring of corporate developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
